Product Description:

• RINVOQ contains the active substance upadacitinib.

 It belongs to a group of drugs called Janus kinase inhibitors. By lowering the activity of an enzyme in the body called Janus kinase, RINVOQ reduces inflammation in the following diseases:

• Rheumatoid arthritis


• Psoriatic arthritis


• Axial spondyloarthritis


• Non-radiographic axial spondyloarthritis


• Ankylosing spondylitis (radiographic axial spondyloarthritis )


• Atopic dermatitis


• Ulcerative colitis

How To Use:

• Always use this medicine exactly as your doctor or pharmacist has told you.


• Contact a doctor or pharmacist if you are unsure.

How much RINVOQ to take:

• If you have rheumatoid arthritis , psoriatic arthritis and axial spondyloarthritis (non-radiographic axial spondyloarthritis and ankylosing spondylitis )


• The recommended dose is one 15 mg tablet once a day.


• If you have atopic dermatitis

Adults :

• The recommended dose is 15 mg or 30 mg as prescribed by the doctor, as one tablet once a day.


• Your doctor may increase or decrease your dose depending on how well the medicine works.

Elderly:

• If you are 65 years of age or older, the recommended dose is 15 mg once a day.

Adolescents (from 12 to 17 years) weighing at least 30 kg:

• The recommended dose is one 15 mg tablet once a day.

If you have ulcerative colitis

• The recommended dose is one 45 mg tablet once daily for 8 weeks.


• Your doctor may choose to extend the initial dose of 45 mg for a further 8 weeks (for a total of 16 weeks).


• This will be followed by one 15 mg or one 30 mg tablet once daily for long-term treatment.


• Your doctor may increase or decrease your dose depending on how you respond to the medicine.

Elderly :

• If you are 65 years of age or older, the recommended dose is 15 mg once daily for long-term treatment.


• Your doctor may reduce your dose if you have kidney problems or you are prescribed certain other medicines.

Caution & Warnings:

• If you are allergic to upadacitinib or any of the other ingredients of this medicine.


• If you have a serious infection (such as pneumonia or bacterial skin infection)


• If you have active tuberculosis


• If you have severe liver problems


• If you are pregnant (see section pregnancy, breastfeeding and contraception)

Ingredients:

RINVOQ 30 mg prolonged-release tablets:

• Each prolonged-release tablet contains upadacitinib hemihydrate, equivalent to 30 mg upadacitinib.

Other ingredients are:

Tablet core:

• Microcrystalline cellulose, mannitol, tartaric acid, hypromellose, silica colloidal anhydrous, magnesium stearate.

Film coating:

• Polyvinyl alcohol, macrogol, talc, titanium dioxide (E 171), red iron oxide


• (E 172).

Product Details: